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Angiotensin blockade in type 2 diabetic renal disease. The avail- tective effects after seven years of treatment with enalapril
able evidence on renal protection in type 2 diabetes mellitus in normotensive type 2 diabetic patients with microalbu-
favors the administration of an angiotensin receptor blocker minuria. However, studies focusing on nephroprotective(ARB) more than that of an angiotensin converting enzyme in-
properties of ACE inhibition in type 2 diabetic patientshibitor (ACEi). This evidence is based on recent studies show-
with overt nephropathy have shown conflicting results [9].ing that losartan and irbesartan can prevent the development of
overt diabetic nephropathy in microalbuminuric type 2 diabetic The MICROHOPE Study (Heart Outcomes Prevention
patients as well as slow the velocity of progression to end-stage Evaluation), in which ramipril was compared to placebo,
renal disease in patients with overt type 2 diabetic nephropathy.
the ACE inhibitor reduced the relative risk of developingThese studies do not deny the possibility that ACEi are equally
overt proteinuria from microalbuminuria by 24% (P effective, but studies of an adequate magnitude are lacking.
These findings on ARB administration do not preclude the im- 0.027) [10].
portance of strict control of blood pressure and proteinuria
and/or albuminuria to avoid or retard renal damage in type 2
diabetic patients. STUDIES WITH ANGIOTENSIN
RECEPTOR BLOCKERS
Recently, three studies have been published showing
Blood pressure (BP) control and proteinuria are the the nephroprotective ability of angiotensin receptor block-
two most relevant actions leading to renal protection in ers [ARB or angiotensin II (Ang II) antagonist] in type 2
type 2 diabetic patients. Recent guidelines agree that ac-
diabetes [4–6].
cording to the available data, BP must be maintained at
The Reduction of Endpoints in Non-insulin dependent
values below 130/80 to 85 mm Hg in diabetic patients [1–3].
diabetes mellitus with the Angiotensin II Antagonist Lo-This goal is even lower—less than 125/75 mm Hg—when
sartan (RENAAL) Study examined the effect of losartanrenal insufficiency and proteinuria in excess of 1 g/day
on 1513 diabetic type 2 subjects with diabetic nephropa-are present. It also is well known that diabetic patients
thy when added to conventional antihypertensive ther-and particularly those with renal disease have difficulties
apy [11]. Three hundred and twenty-seven patients whoachieving an adequate BP control, and that the great
were on losartan therapy reached the primary compositemajority of patients usually require combination therapy
end point (doubling of serum creatinine/development of[4]. Proteinuria is the hallmark of renal disease in diabe-
end-stage renal failure/death), whereas 359 patients ontes and microalbuminuria heralds the development of
placebo did after 3.4 years, a 16% (P  0.02) relativeovert proteinuria. Control of BP together with protein-
risk reduction (RRR). There was no significant effecturia retards or even halts the progression to end-stage
on all cause mortality and proteinuria was reduced byrenal disease [4]. An important drop in proteinuria can
35% (P  0.001). In the Irbesartan Diabetic Nephropa-occur with effective control of BP. Evidence of the bene-
thy Trial (IDNT), the effect of the ARB irbesartan wasficial effects of interruption of the renin-angiotensin sys-
compared to amlodipine and placebo in 1715 hyper-tem (RAS) with angiotensin converting enzyme inhibi-
tensive diabetic type 2 patients with overt nephropathytors (ACEi) has occurred in type 1 diabetic nephropathy
who were treated for a mean duration of 2.6 years [12].as well as in non-diabetic nephropathy [5–7]. The pla-
The primary composite end point was similar as in thecebo-controlled study of Ravid et al raised optimism
RENAAL study and was 20% lower in the irbesartanabout the use of ACEi [8]. Their study showed renopro-
group compared to the placebo group (P  0.02). It was
23% lower in the ARB than in the amlodipine group
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(P  0.006). There were no significant differences inzyme inhibitor, blood pressure control, losartan, irbesartan, diabetic
nephropathy, microalbuminuria, proteinuria. cardiovascular events or in all-cause mortality in either
trial. The Renoprotection with Irbesartan in type 2 dia- 2002 by the International Society of Nephrology
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betic patients with persistent MicroAlbuminuria (IRMA) In summary, the data available on renal protection in
type 2 diabetes could favor the administration of an ARBinvestigators examined the effect of irbesartan on the
development of diabetic nephropathy in 590 subjects more than that of an ACE inhibitor. This hypothesis could
change when the data of the ongoing trials in type 2with type 2 hypertensive diabetes with microalbuminuria
[13]. In the absence of differences in blood pressure, 10 diabetic subjects using an ACE inhibitor are published
[16]. The final data of the ONgoing Telmisartan Aloneof the 194 patients treated with irbesartan 300 mg daily
(5.2%), 19 of 195 patients treated with irbesartan 150 mg and in combination with Ramipril Global Endpoint Trial
(ON TARGET) study also will address possible differ-daily (9.7%), and 30 of 201 patients on placebo devel-
oped diabetic nephropathy (persistent albuminuria200 ences between ACEi and ARB for renal protection, and
whether the combination of the two drugs is superiorg/min, and at least 30% above baseline; hazard ratio
0.30, P  0.001 and 0.61, P  0.08 for both irbesartan [17]. Further data on renal protection will be provided
by the Losartan Intervention for Endpoint reduction ingroups compared to placebo).
Based on the results of these three studies, the Ameri- hypertension (LIFE) [18] and the Valsartan Antihyper-
tensive Long-term Use Evaluation (VALUE) studiescan Diabetes Association has concluded that an angio-
tensin receptor blocker is the drug of choice in type 2 [19] in high-risk hypertensive patients. This latter study
includes a total of 15,313 patients of whom 22.1% haddiabetic patients with nephropathy [3].
proteinuria at baseline and 31.7% were diabetics. Analy-
sis of the evolution of renal function and its relationship
CAVEATS OF THE AVAILABLE STUDIES
to the cardiovascular outcome in the VALUE trial will
In these three studies systolic BP remained above the provide important data that may prove useful in clinical
BP goal suggested by the guidelines (130/85 mm Hg practice.
for the IRMA and 125/75 mm Hg for RENAAL and
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Hospital 12 de Octubre, 28041 Madrid, Spain.
BP in diabetic patients even when the great majority E-mail: Luis_M_Ruilope@teleline.es
received three or more drugs in combination [4, 5]. Thus,
the benefits in all these studies were obtained in the REFERENCES
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